Stryker's sales up 10%, net income up 20%
This article was originally published in Clinica
US company Stryker reported a 10% increase in sales to $240 million in the first quarter, while net income rose 20% to $30 million. Higher shipments of orthopaedic implants, powered surgical instruments and endoscopic equipment led to a 12% rise in US sales. International sales increased 7% as strong shipments of surgical products more than offset currency effects.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.